The calculated panel reactive antibody policy: An advancement improving organ allocation

Mary S. Leffell

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: A major policy change affecting renal organ allocation to sensitized patients in the US was implemented in October, 2009. Extra allocation points are awarded to sensitized patients based on a calculated panel reactive antibody (CPRA). This review will discuss the reasons underlying this policy change and examine the evidence to date of its impact on renal allocation. RECENT FINDINGS: Comparison of both the proportion and transplant rates of sensitized renal transplant candidates during the 6 months prior to the policy implementation and 6 months after implementation showed a significant increase in transplantation of sensitized patients, with the greatest difference occurring among broadly sensitized patients with CPRA values of 80 or greater. Whereas there was a decrease in transplant rates among candidates with CPRA values from 1 to 20, both this decrease and the increased rates among the more highly sensitized recipients were proportional to the distributions of these groups on the wait list. Notably, following the policy change, there was a highly significant decrease in organ refusals due to positive cross-matches with an 83% reduction between the 6-month periods prior to and after the policy implementation. Additional analyses have recently shown the continuation of these trends 1 year after the policy implementation. SUMMARY: Implementation of the CPRA policy on national renal organ allocation in the US has increased efficiency in organ allocation and is helping to facilitate transplantation of broadly sensitized candidates.

Original languageEnglish (US)
Pages (from-to)404-409
Number of pages6
JournalCurrent Opinion in Organ Transplantation
Volume16
Issue number4
DOIs
StatePublished - Aug 2011

Fingerprint

Antibodies
Kidney
Transplants
Transplantation

Keywords

  • calculated panel reactive antibody
  • HLA antibodies
  • panel reactive antibody
  • renal allocation
  • sensitization

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

The calculated panel reactive antibody policy : An advancement improving organ allocation. / Leffell, Mary S.

In: Current Opinion in Organ Transplantation, Vol. 16, No. 4, 08.2011, p. 404-409.

Research output: Contribution to journalArticle

@article{6507166dbe8b48ea8ed5f4a8bdf51eac,
title = "The calculated panel reactive antibody policy: An advancement improving organ allocation",
abstract = "PURPOSE OF REVIEW: A major policy change affecting renal organ allocation to sensitized patients in the US was implemented in October, 2009. Extra allocation points are awarded to sensitized patients based on a calculated panel reactive antibody (CPRA). This review will discuss the reasons underlying this policy change and examine the evidence to date of its impact on renal allocation. RECENT FINDINGS: Comparison of both the proportion and transplant rates of sensitized renal transplant candidates during the 6 months prior to the policy implementation and 6 months after implementation showed a significant increase in transplantation of sensitized patients, with the greatest difference occurring among broadly sensitized patients with CPRA values of 80 or greater. Whereas there was a decrease in transplant rates among candidates with CPRA values from 1 to 20, both this decrease and the increased rates among the more highly sensitized recipients were proportional to the distributions of these groups on the wait list. Notably, following the policy change, there was a highly significant decrease in organ refusals due to positive cross-matches with an 83{\%} reduction between the 6-month periods prior to and after the policy implementation. Additional analyses have recently shown the continuation of these trends 1 year after the policy implementation. SUMMARY: Implementation of the CPRA policy on national renal organ allocation in the US has increased efficiency in organ allocation and is helping to facilitate transplantation of broadly sensitized candidates.",
keywords = "calculated panel reactive antibody, HLA antibodies, panel reactive antibody, renal allocation, sensitization",
author = "Leffell, {Mary S.}",
year = "2011",
month = "8",
doi = "10.1097/MOT.0b013e3283489910",
language = "English (US)",
volume = "16",
pages = "404--409",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - The calculated panel reactive antibody policy

T2 - An advancement improving organ allocation

AU - Leffell, Mary S.

PY - 2011/8

Y1 - 2011/8

N2 - PURPOSE OF REVIEW: A major policy change affecting renal organ allocation to sensitized patients in the US was implemented in October, 2009. Extra allocation points are awarded to sensitized patients based on a calculated panel reactive antibody (CPRA). This review will discuss the reasons underlying this policy change and examine the evidence to date of its impact on renal allocation. RECENT FINDINGS: Comparison of both the proportion and transplant rates of sensitized renal transplant candidates during the 6 months prior to the policy implementation and 6 months after implementation showed a significant increase in transplantation of sensitized patients, with the greatest difference occurring among broadly sensitized patients with CPRA values of 80 or greater. Whereas there was a decrease in transplant rates among candidates with CPRA values from 1 to 20, both this decrease and the increased rates among the more highly sensitized recipients were proportional to the distributions of these groups on the wait list. Notably, following the policy change, there was a highly significant decrease in organ refusals due to positive cross-matches with an 83% reduction between the 6-month periods prior to and after the policy implementation. Additional analyses have recently shown the continuation of these trends 1 year after the policy implementation. SUMMARY: Implementation of the CPRA policy on national renal organ allocation in the US has increased efficiency in organ allocation and is helping to facilitate transplantation of broadly sensitized candidates.

AB - PURPOSE OF REVIEW: A major policy change affecting renal organ allocation to sensitized patients in the US was implemented in October, 2009. Extra allocation points are awarded to sensitized patients based on a calculated panel reactive antibody (CPRA). This review will discuss the reasons underlying this policy change and examine the evidence to date of its impact on renal allocation. RECENT FINDINGS: Comparison of both the proportion and transplant rates of sensitized renal transplant candidates during the 6 months prior to the policy implementation and 6 months after implementation showed a significant increase in transplantation of sensitized patients, with the greatest difference occurring among broadly sensitized patients with CPRA values of 80 or greater. Whereas there was a decrease in transplant rates among candidates with CPRA values from 1 to 20, both this decrease and the increased rates among the more highly sensitized recipients were proportional to the distributions of these groups on the wait list. Notably, following the policy change, there was a highly significant decrease in organ refusals due to positive cross-matches with an 83% reduction between the 6-month periods prior to and after the policy implementation. Additional analyses have recently shown the continuation of these trends 1 year after the policy implementation. SUMMARY: Implementation of the CPRA policy on national renal organ allocation in the US has increased efficiency in organ allocation and is helping to facilitate transplantation of broadly sensitized candidates.

KW - calculated panel reactive antibody

KW - HLA antibodies

KW - panel reactive antibody

KW - renal allocation

KW - sensitization

UR - http://www.scopus.com/inward/record.url?scp=80051787572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051787572&partnerID=8YFLogxK

U2 - 10.1097/MOT.0b013e3283489910

DO - 10.1097/MOT.0b013e3283489910

M3 - Article

C2 - 21666476

AN - SCOPUS:80051787572

VL - 16

SP - 404

EP - 409

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 4

ER -